NEW YORK, Aug. 27, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Orthofix Medical Inc. (NASDAQ: OFIX) between October 11, 2022 and September 12, 2023, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 21, 2024. So what: If you purchased Orthofix common stock during ...

Core Viewpoint - A lawsuit has been filed against Orthofix Medical, Inc. for failing to disclose inappropriate conduct by its management team, which misled investors during the Class Period from October 11, 2022, to September 12, 2023 [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Orthofix's management engaged in conduct that violated the company's code of conduct and was inconsistent with its values [3]. - Investors who purchased Orthofix securities during the Class Period can seek to be appointed as lead plaintiff by October 21, 2024 [2]. Group 2: Company Management Changes - On September 12, 2023, Orthofix announced the termination of its CEO, CFO, and Chief Legal Officer for cause, following an investigation that revealed violations of the company's code of conduct [4]. - The stock price of Orthofix fell by $5.62, or 30.2%, closing at $13.01 per share on the day of the announcement [4].

PHILADELPHIA, Aug. 26, 2024 (GLOBE NEWSWIRE) -- A securities fraud lawsuit has been filed against Orthofix Medical, Inc. ("Orthofix" or the "Company") (NASDAQ: OFIX). The lawsuit is captioned Bernal v. Orthofix Medical, Inc., No. 2:24-cv-00690 (E.D. Tex.), and is filed on behalf of purchasers of Orthofix securities between October 11, 2022 and September 12, 2023, inclusive (the "Class Period"). CLICK HERE TO LEARN MORE ABOUT THIS LAWSUIT. Investors who purchased or acquired Orthofix securities during the Cl ...

Class Action Lawsuit - A class action lawsuit has been filed against Orthofix Medical Inc (NASDAQ: OFIX) alleging securities fraud or other unlawful business practices by the company and certain officers/directors [1][2] - Shareholders who purchased Orthofix securities during the Class Period have until October 21, 2024 to request appointment as Lead Plaintiff [2] Executive Changes - On September 12, 2023, Orthofix announced the immediate appointment of interim CEO, CFO, and Chief Legal Officer following the termination of Keith Valentine, John Bostjancic and Patrick Keran from those roles [2] - The terminations resulted from an investigation that found the executives engaged in repeated inappropriate and offensive conduct violating the company's code of conduct and values [2] Stock Price Impact - Orthofix's stock price fell $5 62 per share or 30 17% to close at $13 01 per share on September 12, 2023 following the executive changes announcement [2] Law Firm Background - Pomerantz LLP, the law firm handling the class action, is a premier firm in corporate, securities and antitrust class litigation with offices in New York, Chicago, Los Angeles, London, Paris and Tel Aviv [3] - Founded over 85 years ago, Pomerantz has recovered billions of dollars in damages for class members in securities fraud and corporate misconduct cases [3]

Group 1 - The article reports that a class action has been filed against Orthofix Medical Inc. on behalf of shareholders who purchased stock between October 11, 2022, and September 12, 2023 [1] - The allegations state that Orthofix's management misled investors about their commitment to ethical standards and corporate values, while in reality, they engaged in inappropriate conduct [2] - Following the announcement of the termination of key executives, the company's stock price dropped by $5.62, or over 30%, closing at $13.01 per share on September 13, 2023 [2] Group 2 - Shareholders interested in participating as lead plaintiffs must submit their applications by October 21, 2024, and can remain absent class members if they choose not to participate [2] - Robbins LLP, the law firm handling the case, has a history of recovering over $1 billion for shareholders and focuses on holding company executives accountable [4]

ATLANTA, Aug. 22, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ: OFIX). The lawsuit alleges that Orthofix's management team was engaged in "repeated inappropriate and offensive conduct that violated multiple code of conduct requirements," which was "inconsistent with the Company's values and culture." When the truth about the Company's management team was revealed, the price of Orthofix common stock suffered sha ...

NEW YORK, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of Texas on behalf of all persons or entities who purchased or otherwise acquired Orthofix Medical, Inc. ("Orthofix" or the "Company") (NASDAQ: OFIX) securities between October 11, 2022, and September 12, 2023, inclusive (the "Class Period"). The lawsuit seeks to recover damages for the Company's investors under the ...

Company Overview - Orthofix Medical Inc. has received FDA 510(k) clearance for the Fitbone Transport and Lengthening System, which is designed to treat large bone defects in the femur and tibia due to trauma or other conditions [5] - The Fitbone system is the only intramedullary nail intended to extend or transfer bone in a single surgical procedure, allowing for significant advancements in limb restoration and deformity repair [5][6] Product Details - The Fitbone TAA Intramedullary Lengthening System is intended for limb lengthening of the femur and tibia, enabling axial and torsional corrections as part of the procedure [2] - The system incorporates advanced technology, including a motorized intramedullary nail and an external control set, allowing patients to manage the distraction phase at home [6] - The Fitbone system has been integrated into the OrthoNext digital platform, which enhances preoperative planning and limb correction accuracy [4] Market Performance - In the past six months, Orthofix Medical's shares have increased by 4.2%, outperforming the industry average rise of 1.9% [8] - The global orthopedic extension devices market was valued at $937.2 million in 2023 and is projected to grow at a rate of 4% from 2023 to 2030, indicating potential revenue growth for Orthofix Medical post-FDA clearance [11] Competitive Position - Orthofix Medical is noted as the only orthopedic company providing a full range of internal and external fixation options for limb restoration and deformity repair [3]

SOURCE The Schall Law Firm LOS ANGELES, July 9, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ: OFIX) for violations of the securities laws. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, ...

LOS ANGELES, May 16, 2024 (GLOBE NEWSWIRE) -- MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market, today announced that Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, has been selected as winner of the "Best Patient Experience Solution" award in the 8th annual MedTech Breakthrough Awards program. The 2024 MedTech Breakthrough Award re ...